What is the latest SUNPHARMA stock price?
The latest stored price for SUNPHARMA is Rs 1,902.40 as of 2026-08-21.
gimli
SUNPHARMA stock AI analysis
SUNPHARMA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SUN PHARMACEUTICAL IND L is a large-cap stock in Healthcare. This Gimli page shows the latest available SUNPHARMA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,902.40
1W return
-1.43%
1M return
-3.03%
3M return
+0.59%
6M return
+10.32%
1Y return
+15.99%
Market cap
₹456,449.49 cr
PE
37.68
PB
5.44
ROE
+15.50%
ROCE
+14.86%
RSI
43.08
Turnover
₹283.83 cr
Why it can matter in screens
- Momentum: SUNPHARMA is below 50DMA, above 200DMA; RSI is 43.08.
- Returns: 1D -0.08%, 1W -1.43%, 1M -3.03%, 3M +0.59%, 1Y +15.99%.
- Trend levels: 52W high ₹2,046.90, 52W low ₹1,756.80, off high -7.06%.
- Liquidity: latest turnover is ₹283.83 cr; volume vs 20D is +0.64%.
- Valuation/profitability: PE 37.68, PB 5.44, ROE +15.50%, ROCE +14.86%.
- Growth: 3Y sales CAGR +10.39%, 3Y profit CAGR +10.65%.
Quick Answers
Is SUNPHARMA above its 50DMA and 200DMA?
SUNPHARMA is below 50DMA, above 200DMA. The latest 50DMA is 1,912.60 and the latest 200DMA is 1,792.16.
What are SUNPHARMA PE, ROE and ROCE?
SUNPHARMA has PE 37.68, ROE +15.50%, and ROCE +14.86% in Gimli's latest available snapshot.
How has SUNPHARMA performed recently?
SUNPHARMA has returned -3.03% over 1 month, +0.59% over 3 months, and +15.99% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 15,183.55 cr | 4,937.20 cr | 2,894.79 cr | 12.10 |
| 2026-03-31 | 14,559.75 cr | 4,412.70 cr | 2,714.03 cr | 11.30 |
| 2025-12-31 | 15,469.07 cr | 5,037.85 cr | 3,368.81 cr | 14.00 |
| 2025-09-30 | 14,948.00 cr | 4,997.00 cr | 3,137.00 cr | 13.00 |
| 2025-06-30 | 13,786.07 cr | 3,948.12 cr | 2,278.63 cr | 9.50 |
| 2025-03-31 | 12,815.58 cr | 3,967.28 cr | 2,149.88 cr | 9.00 |
| 2024-12-31 | 13,436.94 cr | 4,158.47 cr | 2,903.38 cr | 12.10 |
| 2024-09-30 | 13,264.22 cr | 4,292.96 cr | 3,040.16 cr | 12.70 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 58,220.11 cr | 18,395.64 cr | 11,479.42 cr | 47.80 |
| 2025-03-31 | 52,041.25 cr | 16,558.88 cr | 10,929.04 cr | 45.60 |
| 2024-03-31 | 47,758.45 cr | 13,883.15 cr | 9,576.38 cr | 39.90 |
| 2023-03-31 | 43,278.87 cr | 12,110.86 cr | 8,473.58 cr | 35.30 |
| 2022-03-31 | 16,782.86 cr | 6,752.41 cr | -99.99 cr | -0.40 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 108,785.22 cr | 9,770.51 cr | 4,627.32 cr | 83,879.74 cr |
| 2025-03-31 | 92,100.58 cr | 10,268.77 cr | 2,362.19 cr | 72,485.95 cr |
| 2024-03-31 | 85,499.65 cr | 9,285.65 cr | 3,273.67 cr | 67,125.94 cr |
| 2023-03-31 | 80,743.59 cr | 4,623.73 cr | 6,885.87 cr | 59,315.47 cr |
| 2022-03-31 | 69,799.87 cr | 4,508.25 cr | 1,290.30 cr | 51,066.11 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 12,419.18 cr | 8,809.81 cr | n/a |
| 2025-03-31 | 14,072.09 cr | 11,943.51 cr | n/a |
| 2024-03-31 | 12,134.98 cr | 9,933.17 cr | n/a |
| 2023-03-31 | 4,959.33 cr | 2,873.75 cr | n/a |
| 2022-03-31 | 8,984.54 cr | 7,489.50 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +54.48% | +14.53% | +22.18% | +12.84% | +8.81% | +1.65% |
| 2026-03-31 | +54.48% | +15.93% | +21.11% | +11.96% | +8.48% | +1.42% |
| 2025-12-31 | +54.48% | +16.12% | +20.82% | +12.09% | +8.58% | +0.97% |
| 2025-09-30 | +54.48% | +16.55% | +20.23% | +12.41% | +8.73% | +0.97% |
| 2025-06-30 | +54.48% | +17.26% | +19.50% | +12.63% | +8.77% | +0.88% |
| 2025-03-31 | +54.48% | +17.96% | +18.70% | +12.21% | +8.87% | +0.88% |
| 2024-12-31 | +54.48% | +18.05% | +18.55% | +12.24% | +8.92% | +0.69% |
| 2024-09-30 | +54.48% | +18.02% | +18.61% | +12.11% | +8.89% | +0.79% |
| 2024-06-30 | +54.48% | +17.23% | +19.28% | +12.78% | +9.01% | +1.07% |
| 2024-03-31 | +54.48% | +17.72% | +18.83% | +12.21% | +8.97% | +2.05% |
| 2023-12-31 | +54.48% | +17.07% | +19.52% | +12.93% | +8.92% | +2.44% |
| 2023-09-30 | +54.48% | +16.79% | +19.67% | +13.07% | +9.06% | +2.44% |
| 2023-06-30 | +54.48% | +16.48% | +19.75% | +13.16% | +9.29% | +2.29% |
| 2023-03-31 | +54.48% | +16.89% | +19.24% | +12.91% | +9.39% | +1.78% |
| 2022-12-31 | +54.48% | +16.87% | +19.14% | +12.46% | +9.51% | +1.92% |
| 2022-09-30 | +54.48% | +16.00% | +19.71% | +12.22% | +9.82% | +2.53% |
| 2022-06-30 | +54.48% | +0.00% | +34.61% | n/a | n/a | +4.04% |
| 2022-03-31 | +54.48% | +0.00% | +34.46% | n/a | n/a | +5.57% |
| 2021-12-31 | +54.48% | +0.00% | +33.99% | n/a | n/a | +4.79% |
| 2021-09-30 | +54.48% | +0.00% | +33.80% | n/a | n/a | +6.52% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
| DRREDDY | DR. REDDY S LABORATORIES | 97,804.91 cr | 29.535819 | +9.23% | -7.98% |
Try these prompts
- Analyze SUN PHARMACEUTICAL IND L with valuation, momentum and industry peers
- Compare SUNPHARMA with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare SUNPHARMA with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.